skip to main content

Lowenstein Sandler LLP | The contents of this website contain attorney advertising. | Results may vary depending on your particular facts and legal circumstances.

Search
Smart Search Icon
Header Search

Recent Searches

Clear all Searches

Relevant Insights

Featured Content

view all search results
Search Close
Hamburger
profile Icon for Mobile

James C. Shehan

Senior Counsel
Chair, FDA Regulatory Practice

New York
T: +1 646.414.6897 F: +1 973.597.2400 jshehan@lowenstein.com
  • BIO
  • EXPERIENCE
  • NEWS & INSIGHTS

See more section

Life sciences companies look to James C. Shehan as a pharmaceutical lawyer for innovative legal strategies that minimize risk and move their businesses forward. As a seasoned health care executive and pharmaceutical lawyer, he is well-versed in complex regulatory and commercial issues related to drug development, life cycle management, compliance matters, internal investigations, and transactions.

Jim's extensive pharmaceutical and health care industry expertise includes mergers and acquisitions, licensing, litigation, intellectual property, securities, and corporate governance, as well as regulatory issues. Known for his deep knowledge of Food and Drug Administration (FDA) regulatory matters, Jim is a trusted advisor to clients on the development and commercialization of pharmaceutical products, medical devices, and food products. He also has a deep understanding of the emerging field of biosimilars.

Prior to joining Lowenstein Sandler, Jim was of counsel at Hyman, Phelps & McNamara in Washington, D.C. Previously, he was General Counsel and Head of Government Affairs and Quality at Novo Nordisk, one of the most successful global health care companies. During his tenure, Jim oversaw all legal issues, helped establish the company as the market leader in diabetes, and played a key role in the success of several other therapies. Additionally, Jim served as Corporate Counsel at Pfizer, where he advised management on various matters, including the company's compliance with manufacturing, clinical, and laboratory processes. At the start of his career, Jim was an associate in the FDA law group at Sutherland, Asbill & Brennan, and worked at the FDA as a regulatory counsel in the office of the Associate Commissioner for Health Affairs.

A frequent writer and speaker, Jim is sought after for his perspective on the regulatory, legal, and policy challenges shaping the global health care industry. He has spoken at various industry conferences, congressional briefings, and FDA public hearings.

  • Represented Hildred Capital Partners, LLC and its portfolio company Crown Laboratories, Inc., a global innovative leader in the skincare industry, in Crown’s $924M merger agreement with Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings.

Education

  • Georgetown University Law Center (J.D. 1985)

    Columbia College, Columbia University (B.A. 1982), Biology, French Concentration

Affiliations

  • Healthcare Institute of New Jersey (2005-2012, vice-chair 2012)
    • Trustee
  • Healthcare Leadership Council (2006-2012)
    • Board Member
  • American Friends of the Statens Museum for Kunst (Denmark’s National Gallery) (former Chairman)
    • Board Member
  • National Association of Manufacturers (2009-2012)
    • Board Member
  • PhRMA Law Section Executive Committee
    • Company Representative
  • BIO General Counsel Committee
    • Company Representative

Admissions

  • New York
  • District of Columbia

Related Areas